Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Huober, Jens; Minckwitz, Gϋnter von; Denkert, Carsten; Tesch, Hans; Weiß, Erich; Zahm, Dirk M.; Belau, A.; Khandan, F; Hauschild, Maik; Thomssen, Christoph; Högel, Bernhard; Darb‐Esfahani, Silvia; Mehta, Keyur; Loibl, Sibylle

doi:10.1007/s10549-010-1103-9

Cited by 247 publications

(161 citation statements)

References 22 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…Biologic subclassification using ER, PR, and HER2 was performed. Luminal A tumors were defined as ER+, PR+, and HER2−; Luminal B tumors were defined as ER+, PR−, and HER2− or ER+, PR+, and HER2+; HER2 like tumor was defined as ER−, PR+, and HER2+; and triple negative tumors were negative for ER, PR, and HER2 (Huober et al 2010). …”

Section: Methodsmentioning

confidence: 99%

Elevated Serum Levels of Heat Shock Protein 70 Are Associated with Breast Cancer

Günaldı

Afşar

Okuturlar

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequent cause of cancer death in women throughout the world. Thus, it is necessary to establish sensitive screening, diagnosis and treatment methods for BC. Heat shock protein 70 (HSP70) is an important cellular stress response protein that protects cells from apoptosis. Recent studies have shown that serum HSP70 levels may provide clinically important information in various types of cancer. HSP70 is also overexpressed in BC, which is known to be associated with cancer progression, apoptosis and cell proliferation. However, the serum level of HSP70 and its diagnostic and prognostic potential in BC have not been investigated yet. The aim of this study was to determine the usefulness of serum HSP70 level as a diagnostic test and its predictive value in patients with BC. This prospective study consisted of 45 female patients diagnosed with BC and 16 healthy women who were matched for age and body mass index (BMI). Enzyme-linked immunosorbent assay (ELISA) technique was used to measure the serum level of HSP70. The serum level of HSP70 was significantly higher in patients with BC than in the healthy control group (5.98 ± 2.05 vs. 1.49 ± 0.47 ng/ml, p = 0.001). HSP70 level > 2.41 ng/ml was the best cutoff value to predict BC (97.78% sensitivity and 93.75% specificity). This study shows that HSP70 can be used as an adjunct to other diagnostic tests for BC and may be helpful for identifying patients at increased risk of BC.

show abstract

Section: Methodsmentioning

confidence: 99%

Elevated Serum Levels of Heat Shock Protein 70 Are Associated with Breast Cancer

Günaldı

Afşar

Okuturlar

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…The GeparTrio study enrolled women with operable as well as locally advanced breast carcinomas and was organized by the German Breast Group between 2002 and 2005 [9][10][11]. After two cycles with TAC (docetaxel 75 mg/m 2 , doxorubicin 50 mg/m 2 , cyclophosphamide 500 mg/m 2 ), patients were randomized depending on their clinical response.…”

Section: Clinical Study Backgroundmentioning

confidence: 99%

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

Noske

Loibl

Darb‐Esfahani

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In contrast, the definition of labc was found to be "more conservative" in the trials than in the consensus survey. However, of the assessed rcts, twelve 5,8,9,11,13,14,21,32,34,36,38,39,42 showed complete concordance with the expert consensus. The experts reached a strong consensus that lumpectomy be considered an option for surgical management after nat.…”

Section: Comparing Consensus Statements With the Evidencementioning

confidence: 77%

“…Overall, we determined that the trials were "less conservative" (Table i) than the expert consensus . However, of the assessed publications, eleven 2,5,6,8,11,13,14,17,18,25,26,41,42 used definitions of pcr that completely aligned with the expert survey. In contrast, the definition of labc was found to be "more conservative" in the trials than in the consensus survey.…”

Section: Comparing Consensus Statements With the Evidencementioning

confidence: 99%

A Canadian National Expert Consensus on Neoadjuvant Therapy for Breast Cancer: Linking Practice to Evidence and Beyond

et al. 2015

View full text Add to dashboard Cite

BackgroundUse of the neoadjuvant approach to treat breast cancer patients has increased since the early 2000s, but the overall pathway of care for such patients can be highly variable. The aim of our project was to establish a multidisciplinary consensus among clinicians with expertise in neoadjuvant therapy (nat) for breast cancer and to determine if that consensus reflects published methods used in randomized controlled trials (rcts) in this area.MethodsA modified Delphi protocol, which used iterative surveys administered to 85 experts across Canada, was established to obtain expert consensus concerning all aspects of the care pathway for patients undergoing nat for breast cancer. All rcts published between January 1, 1967, and December 1, 2012, were systematically reviewed. Data extracted from the rcts were analyzed to determine if the methods used matched the expert consensus for specific areas of nat management. A scoring system determined the strength of the agreement between the literature and the expert consensus.ResultsConsensus was achieved for all areas of the pathway of care for patients undergoing nat for breast cancer, with the exception of the role of magnetic resonance imaging in the pre-treatment or preoperative setting. The levels of agreement between the consensus statements and the published rcts varied, primarily because specific aspects of the pathway of care were not well described in the reviewed literature.ConclusionsA true consensus of expert opinion concerning the pathway of care appropriate for patients receiving nat for breast cancer has been achieved. A review of the literature illuminated gaps in the evidence about some elements of nat management. Where evidence is available, agreement with expert opinion is strong overall. Our study is unique in its approach to establishing consensus among medical experts in this field and has established a pathway of care that can be applied in practice for patients receiving nat.

show abstract

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Cited by 247 publications

References 22 publications

Elevated Serum Levels of Heat Shock Protein 70 Are Associated with Breast Cancer

Elevated Serum Levels of Heat Shock Protein 70 Are Associated with Breast Cancer

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

A Canadian National Expert Consensus on Neoadjuvant Therapy for Breast Cancer: Linking Practice to Evidence and Beyond

Contact Info

Product

Resources

About